Overview

A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C

Status:
Unknown status

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to undertake an initial evaluation of the safety, tolerability, antiviral effect, and pharmacokinetics of celgosivir in combination with peginterferon alfa-2b and ribavirin in patients with chronic HCV infection.

Phase:

Phase 2

Details

Lead Sponsor:

BioWest Therapeutics Inc

Treatments:

Antiviral Agents
Interferon-alpha
Peginterferon alfa-2b
Ribavirin